Goldman Sachs Group Inc Inozyme Pharma, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 447,317 shares of INZY stock, worth $1.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
447,317
Previous 361,868
23.61%
Holding current value
$1.2 Million
Previous $1.61 Million
45.01%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding INZY
# of Institutions
90Shares Held
53MCall Options Held
3.7KPut Options Held
5.8K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.67MShares$15.3 Million0.05% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$12.1 Million18.53% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$11.5 Million2.12% of portfolio
-
Eventide Asset Management, LLC Boston, MA4.13MShares$11.1 Million0.38% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.8MShares$10.2 Million0.68% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $108M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...